{"id":36864,"date":"2020-09-10T09:00:00","date_gmt":"2020-09-10T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&#038;p=36864"},"modified":"2023-09-06T16:49:13","modified_gmt":"2023-09-06T14:49:13","slug":"ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/","title":{"rendered":"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE"},"content":{"rendered":"<ul>\n<li style=\"margin-bottom:3px\">Les sept abstracts soumis pour pr\u00e9sentation repr\u00e9sentent la plus large participation d\u2019Ipsen \u00e0 la r\u00e9union annuelle de l\u2019ASBMR, la premi\u00e8re organisation scientifique mondiale pour la recherche sur la sant\u00e9 osseuse.<\/li>\n<li style=\"margin-bottom:3px\">Les donn\u00e9es d\u2019Ipsen r\u00e9v\u00e8lent des avanc\u00e9es potentielles dans la compr\u00e9hension de la fibrodysplasie ossifiante progressive (FOP), notamment des enseignements cl\u00e9s sur le conception de l\u2019\u00e9tude, l\u2019histoire naturelle de la pathologie, les biomarqueurs, les options th\u00e9rapeutiques exp\u00e9rimentales et les mesures des r\u00e9sultats rapport\u00e9s par les patients.<\/li>\n<\/ul>\n<p><b>PARIS, FRANCE, le 10 septembre 2020 \u2013 <\/b>Ipsen (Euronext : IPN : ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que de nouvelles donn\u00e9es concernant le portefeuille croissant du Groupe dans l\u2019aire th\u00e9rapeutique des Maladies Rares seront partag\u00e9es lors de sept pr\u00e9sentations \u00e0 l\u2019occasion de la r\u00e9union annuelle de l\u2019<em>American Society for Bone and Mineral Research<\/em> (ASBMR), qui se d\u00e9roulera du 11 au 15 septembre 2020. Ipsen va notamment pr\u00e9senter les r\u00e9sultats de son essai MOVE (lors de la session orale \u00ab Novel Therapies for Rare Bone Disease \u00bb le samedi 12 septembre de 11h00 \u00e0 12h15 ET), la premi\u00e8re et la seule \u00e9tude multicentrique de Phase III sur la fibrodysplasie ossifiante progressive (FOP). Le Docteur Robert Pignolo, Division de m\u00e9decine g\u00e9riatrique et de g\u00e9rontologie, D\u00e9partement de m\u00e9decine interne, Mayo Clinic, pr\u00e9sentera les donn\u00e9es de l\u2019\u00e9tude du m\u00e9dicament exp\u00e9rimental par voie orale palovarot\u00e8ne dans la r\u00e9duction du volume de nouvelles ossifications h\u00e9t\u00e9rotopiques (OH) chez 107 patients enfants et adultes atteints de FOP.1 Les r\u00e9sultats d\u2019efficacit\u00e9 de l\u2019essai MOVE ont \u00e9t\u00e9 compar\u00e9s avec les donn\u00e9es de patients n\u2019ayant pas re\u00e7u de traitement dans le cadre de l\u2019\u00e9tude Ipsen de l\u2019histoire naturelle (Natural History Study, NHS) 2. Les r\u00e9sultats de l\u2019essai MOVE en mati\u00e8re de tol\u00e9rance seront \u00e9galement pr\u00e9sent\u00e9s.<\/p>\n<p>\u00ab <em>Notre passion et notre engagement \u00e0 mieux comprendre les maladies rares ont \u00e9t\u00e9 un catalyseur de progr\u00e8s dans ce programme de recherche. Nous sommes fiers de pr\u00e9senter les donn\u00e9es que nous avons obtenues lors de la r\u00e9union annuelle de l\u2019ASBMR 2020,<\/em> \u00bb a d\u00e9clar\u00e9 Howard Mayer, M.D., Vice-Pr\u00e9sident ex\u00e9cutif, Directeur de la Recherche et du D\u00e9veloppement chez Ipsen. \u00ab<em> La collaboration est essentielle dans la recherche et le d\u00e9veloppement de traitements pour les maladies rares. Nous sommes impatients de poursuivre nos travaux avec des leaders d\u2019opinion, des cliniciens, la communaut\u00e9 d\u2019associations de patients et les autorit\u00e9s r\u00e9glementaires pour capitaliser sur nos recherches et d\u00e9velopper des agents th\u00e9rapeutiques potentiels dans les maladies rares, y compris pour les patients atteints de FOP. <\/em>\u00bb<\/p>\n<p>Quatre posters seront pr\u00e9sent\u00e9s sur les donn\u00e9es de l\u2019\u00e9tude NHS d\u2019Ipsen, qui repr\u00e9sente la plus grande \u00e9tude sur la FOP de ce type au monde. Elle constitue la premi\u00e8re \u00e9tude longitudinale mondiale, multicentrique con\u00e7ue pour mesurer la progression de la maladie sur trois ans.2 Les r\u00e9sultats de l\u2019\u00e9tude NHS confirment que la mesure de l\u2019OH est un moyen viable de surveiller l\u2019\u00e9volution de la FOP et d\u2019\u00e9valuer l\u2019effet potentiel du traitement pendant cette p\u00e9riode.<br \/>\nSuivez Ipsen sur Twitter via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sTpwt7uh_klpxcaiDjDB2xpFrFdsDvkNL1ttPPV7ToU_cR0l6-Uxflp-RyyNgTq7IhXLEUnzy4Rm_L2f4gLSvi09JK5Xfl59K81uAF1f3v4=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>@IpsenGroup<\/b><\/a> et tenez-vous au courant des informations et actualit\u00e9s de la conf\u00e9rence 2020 de l\u2019ASBMR en utilisant le hashtag #ASBMR2020.<\/p>\n<p><b>R\u00e9capitulatif des pr\u00e9sentations d\u2019Ipsen lors de la r\u00e9union annuelle de l\u2019ASBMR 2020 :<\/b><\/p>\n<table style=\"border-collapse: collapse;width:731px;border-collapse:collapse\">\n<tr>\n<td>M\u00e9dicament\/Pathologie<\/td>\n<td>Num\u00e9ro\/titre de l\u2019abstract<\/td>\n<td>Auteurs de l\u2019\u00e9tude<\/td>\n<\/tr>\n<tr>\n<td>Palovarot\u00e8ne\/FOP<\/td>\n<td>Palovarotene (PVO) for Fibrodysplasia Ossificans Progressiva (FOP): Data from the Phase III MOVE Trial<\/td>\n<td>Robert J. Pignolo, Mona Al Mukaddam, Genevi\u00e8ve Baujat, Staffan K. Berglund, Angela M. Cheung, Carmen De Cunto, Patricia Delai, Maja Di Rocco, Nobuhiko Haga, Edward C. Hsiao, Peter Kannu, Richard Keen, Edna E. Mancilla, Donna R. Grogan, Rose Marino, Andrew Strahs, Frederick S. Kaplan<\/td>\n<\/tr>\n<tr>\n<td>Palovarot\u00e8ne\/FOP<\/td>\n<td>Measuring outcomes in ultra-rare bone diseases: Methodology of the palovarotene fibrodysplasia ossificans progressiva (FOP) clinical development program<\/td>\n<td>Robert J. Pignolo, Genevi\u00e8ve Baujat, Matthew A. Brown, Carmen De Cunto, Maja Di Rocco, Edward C. Hsiao, Richard Keen, Mona Al Mukaddam, Andrew Strahs, Donna R. Grogan, Rose Marino, Frederick S. Kaplan<\/td>\n<\/tr>\n<tr>\n<td>FOP<\/td>\n<td>Medications used by individuals with Fibrodysplasia Ossificans Progressiva (FOP): Data from a global natural history study<\/td>\n<td>Richard Keen, Mona Al Mukaddam, Genevi\u00e8ve Baujat, Carmen De Cunto, Edward C. Hsiao, Robert J. Pignolo, Kathleen Harnett, Rose Marino, Frederick S. Kaplan<\/td>\n<\/tr>\n<tr>\n<td>FOP<\/td>\n<td>Longitudinal and flare-up-specific biomarkers in fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study<\/td>\n<td>Robert J. Pignolo, Mona Al Mukaddam, Genevi\u00e8ve Baujat, Carmen De Cunto, Edward C. Hsiao, Richard Keen, Kathleen Harnett, Rose Marino, Frederick S. Kaplan<\/td>\n<\/tr>\n<tr>\n<td>FOP<\/td>\n<td>Use of assistive devices and adaptations by individuals with fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study<\/td>\n<td>Edward C. Hsiao, Mona Al Mukaddam, Genevi\u00e8ve Baujat, Carmen De Cunto, Richard Keen, Robert J. Pignolo, Kathleen Harnett, Rose Marino, Frederick S. Kaplan<\/td>\n<\/tr>\n<tr>\n<td>FOP<\/td>\n<td>A global natural history study of fibrodysplasia ossificans progressiva (FOP): 12-month outcomes<\/td>\n<td>Mona Al Mukaddam, Robert J. Pignolo, Genevi\u00e8ve Baujat, Matthew A. Brown, Carmen De Cunto, Maja Di Rocco, Edward C. Hsiao, Richard Keen, Kim-Hanh Le Quan Sang, Andrew Strahs, Rose Marino, Frederick S. Kaplan<\/td>\n<\/tr>\n<tr>\n<td>FOP<\/td>\n<td>Validity and reliability of the fibrodysplasia ossificans progressiva physical function questionnaire (FOP-PFQ), a patient-reported, disease-specific measure<\/td>\n<td>Robert J. Pignolo, Miriam Kimel, John Whalen, Ariane Kawata, Dennis Revicki, Rose Marino, Frederick S. Kaplan<\/td>\n<\/tr>\n<\/table>\n<p><b>\u00c0 propos du palovarot\u00e8ne<\/b><br \/>\nLe m\u00e9dicament exp\u00e9rimental par voie orale palovarot\u00e8ne est un agoniste hautement s\u00e9lectif du r\u00e9cepteur gamma de l\u2019acide r\u00e9tino\u00efque (RAR\u03b3), actuellement en d\u00e9veloppement comme traitement potentiel pour les patients atteints de fibrodysplasie ossifiante progressive (FOP), un trouble g\u00e9n\u00e9tique extr\u00eamement rare et invalidant. Le palovarot\u00e8ne, qui a obtenu le statut de maladie p\u00e9diatrique ainsi qu\u2019une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e pour le traitement de la FOP, a \u00e9t\u00e9 int\u00e9gr\u00e9 au portefeuille d\u2019Ipsen \u00e0 travers l\u2019acquisition de Clementia Pharmaceuticals en avril 2019.<\/p>\n<p><b>\u00c0 propos de la fibrodysplasie ossifiante progressive (FOP)<\/b><br \/>\nLa fibrodysplasie ossifiante progressive (FOP) est une maladie rare et g\u00e9n\u00e9tique, caract\u00e9ris\u00e9e par un os qui se forme en dehors du squelette normal, dans le muscle, les tendons ou les tissus mous.3 La FOP fait partie des maladies les plus rares sur la plan\u00e8te. Bien qu\u2019il existe environ 1 000 cas recens\u00e9s dans le monde, la pr\u00e9valence connue est d\u2019environ 1,36 par million d\u2019individus4,5.<\/p>\n<p><b>\u00c0 propos d\u2019Ipsen<\/b><br \/>\nIpsen est un groupe biopharmaceutique mondial focalis\u00e9 sur l\u2019innovation et la m\u00e9decine de sp\u00e9cialit\u00e9. Le Groupe d\u00e9veloppe et commercialise des m\u00e9dicaments innovants dans trois domaines th\u00e9rapeutiques cibl\u00e9s \u2013 l\u2019Oncologie, les Neurosciences et les Maladies Rares. Ipsen b\u00e9n\u00e9ficie \u00e9galement d\u2019une pr\u00e9sence significative en Sant\u00e9 Familiale. Avec un chiffre d\u2019affaires de plus de 2,5 milliards d\u2019euros en 2019, Ipsen commercialise plus de 20 m\u00e9dicaments dans plus de 115 pays, avec une pr\u00e9sence commerciale directe dans plus de 30 pays. La R&amp;D d\u2019Ipsen est focalis\u00e9e sur ses plateformes technologiques diff\u00e9renci\u00e9es et innovantes situ\u00e9es au c\u0153ur des clusters mondiaux de la recherche biotechnologique ou en sciences de la vie (Paris-Saclay, France ; Oxford, UK ; Cambridge, US). Le Groupe rassemble plus de 5 800 collaborateurs dans le monde. Ipsen est c\u00f4t\u00e9 en bourse \u00e0 Paris (Euronext : IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Le site Internet d\u2019Ipsen est <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YqDaG8U8RPNxyALu91QBbY0SVXQKjB2c8lJwQ91fyufsargAofmYdLVHTFc9RDaPOXUhoQdCQdoxV9ccAbUBEQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>www.ipsen.com<\/b><\/a>.<\/p>\n<p><b><u>Pour plus d\u2019informations :<\/u><\/b><\/p>\n<table style=\"border-collapse: collapse;width:731px;border-collapse:collapse\">\n<tr>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td><b>M\u00e9dias<\/b><br \/>\nJess Smith<br \/>\nDirecteur Senior, Communication Globale Franchise<br \/>\n+44 (0) 7557 267634<br \/>\n<a href=\"mailto:jess.smith@ipsen.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>jess.smith@ipsen.com<\/b><\/a><\/p>\n<p><b>Communaut\u00e9 financi\u00e8re<\/b><br \/>\nEugenia Litz<br \/>\nVice-Pr\u00e9sident, Relations Investisseurs<br \/>\n+44 (0) 1753 627721<br \/>\n<a href=\"mailto:eugenia.litz@ipsen.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>eugenia.litz@ipsen.com<\/b><\/a><\/td>\n<td colspan=\"2\">Maryann Quinn<br \/>\nDirecteur, Communication Produit Am\u00e9rique du Nord<br \/>\n1-857-529-1151<br \/>\n<a href=\"mailto:Maryann.quinn@ipsen.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>Maryann.quinn@ipsen.com<\/b><\/a><\/p>\n<p>Myriam Koutchinsky<br \/>\nResponsable Relations Investisseurs<br \/>\n+33 (0)1 58 33 51 04<br \/>\n<a href=\"mailto:myriam.koutchinsky@ipsen.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>myriam.koutchinsky@ipsen.com<\/b><\/a><\/td>\n<td><\/td>\n<\/tr>\n<\/table>\n<p><b>R\u00e9f\u00e9rences<\/b><\/p>\n<ol>\n<li style=\"margin-bottom:3px\">Pignolo R et al. Palovarotene (PVO) for fibrodysplasia ossificans progressiva (FOP): Data from the phase III MOVE trial. ASBMR September 2020.<\/li>\n<li style=\"margin-bottom:3px\">Al Mukaddam M et al. A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. J Endocr Soc. 2020;4 (Supplement 1):OR29-05<\/li>\n<li style=\"margin-bottom:3px\">The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations, IFOPA. Accessed: May 2020. Available: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i7Idk0sa7NiXoGSVfFfE62G-OLDWYHmgRqlaY8_xP6yJgHXWQVOWfjurioy6693MA6Uj3cqZMUtCh6FiG1dWexzX63B1RxRAAjcA8cTxRZxtQjTnzASNQ7rBuuMVLwpBDHiDbEcWGu-fq17R9spjYF1Th-SMy-_-KWtjVgCqUC9LavQYL2Fwe0Fl0KS_eNG4k-ehs4hK6UyccFTYB-tNTCbhk5pNMKwvV5EbV1QHEDpx8R5AqJl_6nF-h1V9lh9f\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>http:\/\/fundacionfop.org.ar\/wp-content\/uploads\/2019\/05\/GUIDELINES-May-2019.pdf<\/u><\/a><\/li>\n<li style=\"margin-bottom:3px\">Lilijesthrom M &amp; Bogard B. The Global Known FOP Population. Presented at the FOP Drug Development Forum. Boston, MA; 2016.<\/li>\n<li style=\"margin-bottom:3px\">Baujat et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. <em>Orphanet Journal of Rare Diseases.<\/em> 2017; 12:123.<\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\"> <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li> <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=p5VlRMlDrysmHeUYSay6idrpO6-WnBwQRsgwsaqg9GSUPtbVvsGoazELTK0SmnFKtaXzIlcp2URlNEvAjJEEmMoubvn8YsCXxVrE2e29H4nDr3bKmGZbfz-owa9sImjBMhcs6tTTcNLpUkyhWDwVpOqgTHCslNAx9QaVpiLq54DWb4ED4OwjW01dyj1XDG9X\" title=\"Ipsen-ASBMR-10-Septembre-2020\" rel=\"nofollow noopener\">Ipsen-ASBMR-10-Septembre-2020<\/a><\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3563],"tags":[],"class_list":["post-36864","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-rare-diseases-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-06T14:49:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE\",\"datePublished\":\"2020-09-10T07:00:00+00:00\",\"dateModified\":\"2023-09-06T14:49:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\"},\"wordCount\":1489,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Maladies rares\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\",\"name\":\"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2020-09-10T07:00:00+00:00\",\"dateModified\":\"2023-09-06T14:49:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/","og_site_name":"Global","article_modified_time":"2023-09-06T14:49:13+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE","datePublished":"2020-09-10T07:00:00+00:00","dateModified":"2023-09-06T14:49:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/"},"wordCount":1489,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Maladies rares"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/","name":"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2020-09-10T07:00:00+00:00","dateModified":"2023-09-06T14:49:13+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODljMGU2N2EtOGRlMS00MTQ2LThmM2QtZDQ4Mjg2Y2EzODU4LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-va-presenter-de-nouvelles-donnees-lors-de-la-reunion-annuelle-de-lasbmr-sur-le-traitement-potentiel-de-la-fibrodysplasie-ossifiante-progressive-fop-comprenant-les-resultats-de-l\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Ipsen va pr\u00e9senter de nouvelles donn\u00e9es lors de la r\u00e9union annuelle de l\u2019ASBMR sur le traitement potentiel de la fibrodysplasie ossifiante progressive (FOP), comprenant les r\u00e9sultats de l\u2019\u00e9tude internationale de Phase III MOVE"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36864"}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36864\/revisions"}],"predecessor-version":[{"id":36869,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36864\/revisions\/36869"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}